Prospective cohort study on the effectiveness of influenza and pneumococcal vaccines in preventing pneumonia development and hospitalization

Joon-Young Song, Jin Soo Lee, Seong Heon Wie, Hyo Youl Kim, Jacob Lee, Yu Bin Seo, Hye Won Jeong, Shin Woo Kim, Sun Hee Lee, Kyung Hwa Park, Ji Yun Noh, Wonseok Choi, Hee-Jin Cheong, Woo Joo Kim

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

Pneumonia and acute exacerbation of chronic illness are leading causes of influenza-related hospitalization. Therefore, influenza and pneumococcal vaccinations are strongly recommended for adults with comorbidities. Using a hospital-based influenza surveillance system, we performed a multicenter, prospective cohort study of patients visiting emergency rooms with influenza-like illness (ILI) during the influenza epidemic period in 2013 to 2014. Patients aged≤19 years were enrolled, and clinical data were collected. Multivariate analyses were performed to estimate the effectiveness of influenza and pneumococcal vaccination in preventing pneumonia development and hospitalization. During study periods, 2,262 patients with ILI were registered. Among 2,217 patients with available vaccination records, 31.9% (707 patients) and 9.7% (216 patients) had received influenza and pneumococcal vaccines, respectively. Among patients who had been administered a pneumococcal vaccine, 94.4% had received the 23-valent polysaccharide vaccine (PPV23). The adjusted rates of effectiveness of the influenza vaccine for preventing pneumonia development and hospitalization were 64.0% (95% confidence interval [CI]=29% to 81%) and 35.0% (95% CI=12% to 52%), respectively. Pneumococcal vaccination did not reduce pneumonia development or hospitalization. In conclusion, influenza rather than PPV23 vaccination may reduce pneumonia development and hospitalization in patients with preceding ILI.

Original languageEnglish
Pages (from-to)229-234
Number of pages6
JournalClinical and Vaccine Immunology
Volume22
Issue number2
DOIs
Publication statusPublished - 2015 Jan 1

Fingerprint

Pneumococcal Vaccines
Influenza Vaccines
Human Influenza
Pneumonia
Hospitalization
Cohort Studies
Emergency rooms
Prospective Studies
Vaccination
Polysaccharides
Vaccines
Confidence Intervals
Hospital Emergency Service
Comorbidity
Chronic Disease
Multivariate Analysis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Clinical Biochemistry
  • Microbiology (medical)

Cite this

Prospective cohort study on the effectiveness of influenza and pneumococcal vaccines in preventing pneumonia development and hospitalization. / Song, Joon-Young; Lee, Jin Soo; Wie, Seong Heon; Kim, Hyo Youl; Lee, Jacob; Seo, Yu Bin; Jeong, Hye Won; Kim, Shin Woo; Lee, Sun Hee; Park, Kyung Hwa; Noh, Ji Yun; Choi, Wonseok; Cheong, Hee-Jin; Kim, Woo Joo.

In: Clinical and Vaccine Immunology, Vol. 22, No. 2, 01.01.2015, p. 229-234.

Research output: Contribution to journalReview article

Song, Joon-Young ; Lee, Jin Soo ; Wie, Seong Heon ; Kim, Hyo Youl ; Lee, Jacob ; Seo, Yu Bin ; Jeong, Hye Won ; Kim, Shin Woo ; Lee, Sun Hee ; Park, Kyung Hwa ; Noh, Ji Yun ; Choi, Wonseok ; Cheong, Hee-Jin ; Kim, Woo Joo. / Prospective cohort study on the effectiveness of influenza and pneumococcal vaccines in preventing pneumonia development and hospitalization. In: Clinical and Vaccine Immunology. 2015 ; Vol. 22, No. 2. pp. 229-234.
@article{50abe6453572401381100fcd990c4bea,
title = "Prospective cohort study on the effectiveness of influenza and pneumococcal vaccines in preventing pneumonia development and hospitalization",
abstract = "Pneumonia and acute exacerbation of chronic illness are leading causes of influenza-related hospitalization. Therefore, influenza and pneumococcal vaccinations are strongly recommended for adults with comorbidities. Using a hospital-based influenza surveillance system, we performed a multicenter, prospective cohort study of patients visiting emergency rooms with influenza-like illness (ILI) during the influenza epidemic period in 2013 to 2014. Patients aged≤19 years were enrolled, and clinical data were collected. Multivariate analyses were performed to estimate the effectiveness of influenza and pneumococcal vaccination in preventing pneumonia development and hospitalization. During study periods, 2,262 patients with ILI were registered. Among 2,217 patients with available vaccination records, 31.9{\%} (707 patients) and 9.7{\%} (216 patients) had received influenza and pneumococcal vaccines, respectively. Among patients who had been administered a pneumococcal vaccine, 94.4{\%} had received the 23-valent polysaccharide vaccine (PPV23). The adjusted rates of effectiveness of the influenza vaccine for preventing pneumonia development and hospitalization were 64.0{\%} (95{\%} confidence interval [CI]=29{\%} to 81{\%}) and 35.0{\%} (95{\%} CI=12{\%} to 52{\%}), respectively. Pneumococcal vaccination did not reduce pneumonia development or hospitalization. In conclusion, influenza rather than PPV23 vaccination may reduce pneumonia development and hospitalization in patients with preceding ILI.",
author = "Joon-Young Song and Lee, {Jin Soo} and Wie, {Seong Heon} and Kim, {Hyo Youl} and Jacob Lee and Seo, {Yu Bin} and Jeong, {Hye Won} and Kim, {Shin Woo} and Lee, {Sun Hee} and Park, {Kyung Hwa} and Noh, {Ji Yun} and Wonseok Choi and Hee-Jin Cheong and Kim, {Woo Joo}",
year = "2015",
month = "1",
day = "1",
doi = "10.1128/CVI.00673-14",
language = "English",
volume = "22",
pages = "229--234",
journal = "Clinical and Vaccine Immunology",
issn = "1556-6811",
publisher = "American Society for Microbiology",
number = "2",

}

TY - JOUR

T1 - Prospective cohort study on the effectiveness of influenza and pneumococcal vaccines in preventing pneumonia development and hospitalization

AU - Song, Joon-Young

AU - Lee, Jin Soo

AU - Wie, Seong Heon

AU - Kim, Hyo Youl

AU - Lee, Jacob

AU - Seo, Yu Bin

AU - Jeong, Hye Won

AU - Kim, Shin Woo

AU - Lee, Sun Hee

AU - Park, Kyung Hwa

AU - Noh, Ji Yun

AU - Choi, Wonseok

AU - Cheong, Hee-Jin

AU - Kim, Woo Joo

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Pneumonia and acute exacerbation of chronic illness are leading causes of influenza-related hospitalization. Therefore, influenza and pneumococcal vaccinations are strongly recommended for adults with comorbidities. Using a hospital-based influenza surveillance system, we performed a multicenter, prospective cohort study of patients visiting emergency rooms with influenza-like illness (ILI) during the influenza epidemic period in 2013 to 2014. Patients aged≤19 years were enrolled, and clinical data were collected. Multivariate analyses were performed to estimate the effectiveness of influenza and pneumococcal vaccination in preventing pneumonia development and hospitalization. During study periods, 2,262 patients with ILI were registered. Among 2,217 patients with available vaccination records, 31.9% (707 patients) and 9.7% (216 patients) had received influenza and pneumococcal vaccines, respectively. Among patients who had been administered a pneumococcal vaccine, 94.4% had received the 23-valent polysaccharide vaccine (PPV23). The adjusted rates of effectiveness of the influenza vaccine for preventing pneumonia development and hospitalization were 64.0% (95% confidence interval [CI]=29% to 81%) and 35.0% (95% CI=12% to 52%), respectively. Pneumococcal vaccination did not reduce pneumonia development or hospitalization. In conclusion, influenza rather than PPV23 vaccination may reduce pneumonia development and hospitalization in patients with preceding ILI.

AB - Pneumonia and acute exacerbation of chronic illness are leading causes of influenza-related hospitalization. Therefore, influenza and pneumococcal vaccinations are strongly recommended for adults with comorbidities. Using a hospital-based influenza surveillance system, we performed a multicenter, prospective cohort study of patients visiting emergency rooms with influenza-like illness (ILI) during the influenza epidemic period in 2013 to 2014. Patients aged≤19 years were enrolled, and clinical data were collected. Multivariate analyses were performed to estimate the effectiveness of influenza and pneumococcal vaccination in preventing pneumonia development and hospitalization. During study periods, 2,262 patients with ILI were registered. Among 2,217 patients with available vaccination records, 31.9% (707 patients) and 9.7% (216 patients) had received influenza and pneumococcal vaccines, respectively. Among patients who had been administered a pneumococcal vaccine, 94.4% had received the 23-valent polysaccharide vaccine (PPV23). The adjusted rates of effectiveness of the influenza vaccine for preventing pneumonia development and hospitalization were 64.0% (95% confidence interval [CI]=29% to 81%) and 35.0% (95% CI=12% to 52%), respectively. Pneumococcal vaccination did not reduce pneumonia development or hospitalization. In conclusion, influenza rather than PPV23 vaccination may reduce pneumonia development and hospitalization in patients with preceding ILI.

UR - http://www.scopus.com/inward/record.url?scp=84921985073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921985073&partnerID=8YFLogxK

U2 - 10.1128/CVI.00673-14

DO - 10.1128/CVI.00673-14

M3 - Review article

C2 - 25540271

AN - SCOPUS:84921985073

VL - 22

SP - 229

EP - 234

JO - Clinical and Vaccine Immunology

JF - Clinical and Vaccine Immunology

SN - 1556-6811

IS - 2

ER -